Investigational drug · Phase 3
[18F]-APN-1607
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alzheimer's Disease, Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia.
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
n/a
Any phase or sponsor naming "[18F]-APN-1607"
First trial start
2026
Jan 22, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "[18F]-APN-1607", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer's Disease
- Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "[18F]-APN-1607" as an intervention, largest first.
- Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
NCT07422857 · Phase 3 · Recruiting · JYAMS PET Research & Development Limited · 316 participants · primary completion Dec 1, 2026
- Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.
NCT07752784 · Phase 3 · Recruiting · JYAMS PET Research & Development Limited · 12 participants · primary completion Apr 30, 2027
Newest research
PubMed records naming it or its code names, newest first.
- Radiation dosimetry and pharmacokinetics of the tau PET tracer florzolotau (18F) in healthy Japanese subjects.
Miyamoto M, Okuyama C, Kagawa S, et al. · Ann Nucl Med 2023
- Complementary Utility of Dopamine Transporter and Tau PET Imaging in the Diagnosis of Progressive Supranuclear Palsy: A Case Report.
Jia C, Wu M, Yen TC, et al. · Clin Nucl Med 2022
- In Vivo 18 F-APN-1607 Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross-Sectional and Longitudinal Findings.
Zhou XY, Lu JY, Liu FT, et al. · Mov Disord 2022
- 18F-APN-1607 Tau Positron Emission Tomography Imaging for Evaluating Disease Progression in Alzheimer's Disease.
Xu X, Ruan W, Liu F, et al. · Front Aging Neurosci 2021
- Clinical Utility of 18 F-APN-1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy.
Li L, Liu FT, Li M, et al. · Mov Disord 2021
- Characterization of 18F-PM-PBB3 (18F-APN-1607) Uptake in the rTg4510 Mouse Model of Tauopathy.
Weng CC, Hsiao IT, Yang QF, et al. · Molecules 2020
Also in development for Alzheimer's Disease
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- TrontinemabRO7126209, RG6102Phase 34 trials
Roche (Genentech) · Alzheimers Disease, Alzheimer's Disease
- RemternetugLY3372993Phase 31 trial
Eli Lilly · Alzheimer's Disease
- RO7568282Phase 22 trials
Roche (Genentech) · Parkinson's Disease, Alzheimer's Disease
- VHB937Phase 22 trials
Novartis · Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease
- ABBV-1758Phase 21 trial
AbbVie · Alzheimer's Disease
- E2814Phase 21 trial
Eisai · Alzheimer's Disease
- GSK4527226Phase 21 trial
GSK · Alzheimer's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.